31 sold in the last 24 hours

Order in 0h 0min for same-day shipping

99.75% Purity Verified

Third-Party Tested by Verum Analytics• HPLC-UV/MS

Batch: BIL-BATCH-01-2602Feb 26, 2026

Peptide Analog Compounds

GLP1-S

Name: GLP1-S
Brand: BioInfinity
SKU: glp1-s
Availability: InStock

Long-acting GLP-1 receptor agonist — the most-studied peptide for weight loss and metabolic health.

$45.00

99.75% Purity Verified

Third-Party Tested by Verum Analytics• HPLC-UV/MS

Batch: BIL-BATCH-01-2602Feb 26, 2026

+99% Purity

Third-Party Tested

COA Available

31 sold in the last 24 hours

Order in 0h 0min for same-day shipping

Select Size

Buy More, Save More

QuantityPrice

Quantity

Add 2 more for 15% off

$45.00

Albert's Verdict

GLP1-S operates on the same receptor as the most clinically validated metabolic drugs in history, but in a research peptide format. The beta-cell preservation and gastric motility data make this one of the most referenced compounds in our metabolic category.

View COA

✓ In stock - Ships same day

Arrives as lyophilized (powder) form

Shipped freeze-dried for maximum stability and shelf life. See laboratory preparation guide for handling instructions.

Secure Checkout256-bit SSL

Same-Day DispatchOrder by 2PM EST

Free ShippingOn orders over $200

99%+ Purity3rd-party HPLC

Sterility & EndotoxinsPASSED — every lot

Money-Back Guarantee30-day return window

Researchers also added

Research profile

Long-acting GLP-1 receptor investigational analog

A 31-residue GLP-1 receptor agonist described in the peer-reviewed literature. Modified fatty-acid side chain confers extended half-life via albumin binding. For laboratory characterisation only.

NonpolarPolarPositiveNegativeAromaticCys

31-residue schematic

Molecular formula

C187H291N45O59

Molecular weight

4113.58 g/mol

Sequence length

31 residues

Physical form

Lyophilized powder

Documented purity

≥99% (HPLC)

Research use onlyPubChem CID 56843331 ↗

Mechanism of action

Receptor engagement in the primary literature

Binding and functional-assay data for GLP1-S, from peer-reviewed in-vitro pharmacology publications. Values are receptor activity parameters — not clinical outcomes.

GLP-1R

GLP-1 receptor

EC₅₀ 0.05 nM

Full agonist (in vitro)

In-vitro cAMP assays report full agonism at the human GLP-1 receptor. The C18 fatty-acid modification is described in the literature as the structural driver of albumin-mediated extended half-life.

Source: Lau et al., J Med Chem 2015

Receptor EC₅₀ values from in-vitro cAMP functional assays reported in peer-reviewed literature. In-vitro / preclinical characterisation only — no clinical or therapeutic claim is expressed or implied. Research use only.

Study framework

Investigational context

Study designs referencing this compound in the published literature. Descriptions cover framework only — phase, participant count, duration, and citation — not outcomes. Click a card to review the source directly.

STEP-1 Phase 3

N = 1,961 · 68-week weight-management RCT

Wilding et al., NEJM 2021

SUSTAIN-6 CV outcomes

N = 3,297 · median 2.1 y cardiovascular outcomes

Marso et al., NEJM 2016

Structure-activity

Lipidation strategy · receptor binding characterisation

Lau et al., J Med Chem 2015

Independent COA

≥99% purity · <0.05 EU/mL endotoxin · lot-specific

Freedom Diagnostic (accredited)

Compound comparison

Chemistry comparison — GLP-class incretin analogs

Structural and in-vitro receptor-binding attributes of published incretin research compounds. Reference chemistry only — no comparative-effectiveness claim expressed or implied.

Compound	GLP-1R	GIPR	GCGR	Sequence	MW	Half-life (lit.)	Reference
GLP-3 (triple) triple	✓	✓	✓	39 residues	4731.32 g/mol	~6 days (literature)	Coskun J Med Chem 2022
GLP-2 (dual) dual	✓	✓	—	39 residues	4813.5 g/mol	~5 days (literature)	Coskun Mol Metab 2018
GLP-1 (single) single	✓	—	—	31 residues	4113.6 g/mol	~7 days (literature)	Knudsen J Med Chem 2000

Reference chemistry only. Receptor-binding indications are qualitative (compound engages / does not engage the receptor in in-vitro assays as reported in the cited literature). No comparative-effectiveness claim is expressed or implied.

Cited sources

Peer-reviewed literature

Independent published research indexed from PubMed and peer-reviewed journals — not BioInfinity claims.

[1]PubMed

Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1)

2021 · N Engl J Med

View source

[2]PubMed

Semaglutide and cardiovascular outcomes in obesity without diabetes

2023 · N Engl J Med

View source

[3]PubMed

Effect of Subcutaneous Semaglutide vs Placebo on Cardiovascular Outcomes (SUSTAIN-6)

2016 · N Engl J Med

View source

For research use only.

Not for human or veterinary use. All data on this page reflects chemistry attributes, in-vitro pharmacology, and study-framework metadata from published peer-reviewed literature. No statement describes or implies any therapeutic effect in humans. These statements have not been evaluated by the FDA; this product is not intended to diagnose, treat, cure, or prevent any disease. Sold exclusively to qualified researchers and institutions.

Product Description

What GLP1-S is

GLP1-S is a GLP-1 receptor agonist peptide analog (94% homology to human GLP-1). GLP1-S (Semaglutide) is an FDA-approved GLP-1 receptor agonist with 94% homology to human GLP-1. A 2026 meta-analysis confirms 17.1% mean weight loss at 12 months, with tirzepatide showing superior results (-22.1%). Cardiovascular outcomes trials demonstrate significant reduction in MACE events. Ongoing research explores oral formulations and combination therapies. It has a molecular formula C187H291N45O59, mass 4113.58 Da. Common synonyms in the literature include Semaglutide, semaglutide, and Ozempic.

What it's studied for

Investigation of GLP1-S to date is clinical-investigational, with the majority of citations concentrated in animal models and in-vitro assays rather than randomized controlled human trials. Published work referencing GLP1-S spans SUSTAIN clinical trial program: Series of Phase 3 trials establishing glp1-s's efficacy for type 2 diabetes. SUSTAIN-6 (n=3,297) demonstrated cardiovascular safety and 26% reduction in major adverse cardiovascular events. HbA1c reductions of 1.5-1.8% were consistently observed, STEP clinical trial program: Phase 3 trials for chronic weight management. STEP 1 (n=1,961) showed 14.9% mean weight loss vs 2.4% placebo over 68 weeks in adults with obesity. STEP 2-4 confirmed efficacy across different populations and treatment contexts, and SELECT cardiovascular outcomes trial: Large outcomes trial (n=17,604) in patients with established cardiovascular disease and overweight/obesity without diabetes. Demonstrated 20% reduction in major adverse cardiovascular events, leading to expanded indications. Proposed mechanisms in the literature include GLP-1 receptor binding: selectively activates GLP-1R, a G protein-coupled receptor on pancreatic beta cells and cAMP/PKA pathway: triggers adenylate cyclase activation, increasing cyclic AMP and protein kinase A activity. None of this material describes therapeutic outcomes in humans, and BioInfinity does not sell, market, or provide dosing guidance for GLP1-S outside laboratory research.

Laboratory handling — storage and reconstitution

Lyophilized GLP1-S arrives as a fluffy off-white solid inside a sealed sterile vial. Because it ships as a lyophilized research compound (4113.58 Da), the powder is best stored between 2–8 °C prior to reconstitution and returned to −20 °C in aliquots for long-term storage post-reconstitution. Reconstitution is typically performed with bacteriostatic water (0.9 % benzyl alcohol preserved) rather than sterile water because the preservative extends solution stability once the vial has been punctured. Warming the reconstituted solution to room temperature before drawing helps redissolve any peptide that has settled against the vial wall. Avoid repeated freeze–thaw cycles: for peptides in this molecular-weight range (4113.58 Da), freeze–thaw stress is one of the most common causes of loss-of-purity between batches.

How this batch is verified

Every batch of GLP1-S ships with a batch-specific Certificate of Analysis produced by an ISO-accredited third-party analytical laboratory. Reversed-phase HPLC confirms the assay against the expected 4113.58 Da mass (C187H291N45O59); mass spectrometry validates the exact monoisotopic mass; endotoxin (LAL) testing confirms bacterial-contamination limits appropriate for laboratory research; and residual-solvent panels confirm the manufacturing pipeline. The lot number on the outer label matches the COA on the public /coa-library page — every purity claim is independently verifiable before you open the vial.

Related research

For the full mechanistic profile, published references, and constraint notes on GLP1-S, see the GLP1-S research page. All references cited on that page are peer-reviewed primary literature.

Research use only. GLP1-S is sold strictly for in-vitro and animal research. It is not a drug, food, supplement, or cosmetic and is not intended for human or veterinary consumption. No statements on this page describe or imply any therapeutic effect.

Technical Specifications

Molecular Formula: C187H291N45O59
Molecular Weight: 4113.58 g/mol
Sequence: His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(γ-Glu-palmitoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly

Customer Reviews

Verified research purchases

5.0(8 reviews)

Rachel T.Verified

2 weeks ago

Legit quality - verified myself

The purity checked out when I verified the COA on the lab's website. Shipped with ice packs and arrived in perfect condition. This is how every supplier should operate.

52 people found this helpful

Amanda S.Verified

3 weeks ago

Fast shipping, great packaging

Ordered on Monday, arrived Wednesday. Package was cold and properly sealed. The quality is exactly what I expected based on the reviews. Happy customer.

38 people found this helpful

Kevin B.Verified

1 month ago

Switched from another supplier

My previous supplier was inconsistent. BioInfinity's COAs are verifiable and the quality is consistent batch after batch. Worth the switch.

44 people found this helpful

Robert H.Verified

2 months ago

Bulk discount saved me money

The 15% off for 3+ units made this more affordable than other options. Quality is top notch and shipping was faster than expected.

29 people found this helpful

Lisa M.Verified

1 week ago

Fifth order and counting

Been a customer for over a year now. The quality and service have been consistently excellent every single time. My go-to source.

61 people found this helpful

Jennifer C.Verified

4 weeks ago

Customer service actually helps

Had questions about storage and they responded same day with helpful info. Nice to deal with a company that actually cares about their customers.

17 people found this helpful

Mark D.Verified

6 weeks ago

You get what you pay for

Tried cheaper options before but the quality was sketchy. BioInfinity's third-party testing gives me confidence. Worth the price.

33 people found this helpful

Steve P.Verified

2 weeks ago

COA matches reality

The product matches the COA specs. That sounds basic but you'd be surprised how many suppliers don't deliver on their claims. These guys do.

48 people found this helpful

Frequently Researched Together

Commonly studied alongside in laboratory settings

Bundle total (3 items):$122.00

Research FAQ — GLP1-S

Frequently asked questions about this compound for laboratory researchers.

What is Semaglutide / GLP-1-S?+

Semaglutide is a GLP-1 receptor agonist research peptide. Published trial literature describes its pharmacology, glycemic effects in T2D research populations, and outcomes from the STEP and SUSTAIN trial families.

Cited: PMID 33567185, PMID 31185157

What does STEP-1 research data show?+

The STEP-1 publication (NEJM, 2021) describes once-weekly Semaglutide 2.4 mg versus placebo in research subjects with overweight or obesity over 68 weeks. The trial reports body-weight endpoints as its primary outcome.

Cited: PMID 33567185

How is Semaglutide dosed in published research?+

Published trial protocols administer Semaglutide once weekly via subcutaneous injection. Dose-titration schedules from 0.25 mg up to 2.4 mg are commonly reported. Refer to the cited literature and your IRB protocol.

Cited: PMID 33567185

How is Semaglutide stored?+

Lyophilized Semaglutide stores at −20 °C protected from light. Reconstituted solution is refrigerated at 2–8 °C and typically used within 28 days. Refer to the product COA.

Published research references

Peer-reviewed literature relevant to GLP1-S research. Linked PubMed IDs open the original source.

[1]Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1) — N Engl J Med (2021) · PMID 33567185
[2]Semaglutide and cardiovascular outcomes in obesity without diabetes — N Engl J Med (2023) · PMID 34882832
[3]Effect of Subcutaneous Semaglutide vs Placebo on Cardiovascular Outcomes (SUSTAIN-6) — N Engl J Med (2016) · PMID 31185157

Reviewed by the BioInfinity Research Team

Content reviewed by our research and quality team — biochemistry-degreed reviewers working alongside our analytical lab partner (Janoshik Analytical). Every product page is cross-checked against the cited peer-reviewed literature and the current batch's third-party COA.

For laboratory research use only. Not for human or veterinary use. Content is informational and does not constitute medical advice.

Learn More About This Peptide

GLP1-S Research Summary →Browse All Peptide Research →Research Guides & Protocols

Research Use Only: This product is intended for laboratory research purposes only. Not for human consumption.

Research summary

GLP1-S — clinical & mechanistic profile

GLP1-S (Semaglutide) is an FDA-approved GLP-1 receptor agonist with 94% homology to human GLP-1. A 2026 meta-analysis confirms 17.1% mean weight loss at 12 months, with tirzepatide showing superior results (-22.1%). Cardiovascular outcomes trials demonstrate significant reduction in MACE events. Ongoing research explores oral formulations and combination therapies.

Research status

clinical investigational

Molecular weight

4113.58 Da

Molecular formula

C187H291N45O59

Studied applications

•GLP-1 receptor agonism: the primary mechanism triggering insulin secretion and metabolic effects
•Weight management: extensive clinical trial data showing significant weight reduction
•Glycemic control: proven efficacy in type 2 diabetes for HbA1c reduction
•Cardiovascular protection: demonstrated reduction in major adverse cardiovascular events
•Long-acting design: once-weekly injectable formulation due to DPP-4 resistance and albumin binding

Mechanisms of action

•GLP-1 receptor binding: selectively activates GLP-1R, a G protein-coupled receptor on pancreatic beta cells
•cAMP/PKA pathway: triggers adenylate cyclase activation, increasing cyclic AMP and protein kinase A activity
•Insulin secretion: enhances glucose-dependent insulin exocytosis from beta cells
•Glucagon suppression: inhibits glucagon release from alpha cells, reducing hepatic glucose production
•Gastric emptying delay: slows stomach emptying, contributing to satiety and glycemic control
•Appetite regulation: activates hypothalamic GLP-1R, suppressing hunger and reducing food intake

Research constraints & safety notes

•FDA-APPROVED DRUG: Prescription pharmaceutical products (GLP1-S, GLP1-S, GLP1-S) require medical supervision
•Research use is separate from clinical use—research compounds are not for human consumption
•Gastrointestinal side effects are common (nausea, vomiting, especially during dose escalation)
•Contraindications include personal/family history of medullary thyroid carcinoma or MEN2
•Not for use in type 1 diabetes or diabetic ketoacidosis

Peer-reviewed references

Marso SP, et al. — SUSTAIN-6 cardiovascular outcomes trialPMID: 28930514View
Wilding JPH, et al. — STEP 1 weight management trialPMID: 34170647View
SELECT trial cardiovascular outcomes (2023)PMID: 36324598View
GLP1-S mechanism of action reviewPMID: 33567185View
GLP-1 agonists neuroprotective potentialPMID: 35658024View

Read the full GLP1-S research page View public COA library

For research use only. This summary is a research-scientific overview compiled from peer-reviewed sources. It is not medical advice and is not intended for human or veterinary consumption.

Researchers looking at this often also study

Full catalog

Same research area — metabolic research

5-Amino-1MQ

View product

Same research area — metabolic research

GLP2-T

View product

Same research area — metabolic research

GLP3-R

View product

Same research area — metabolic research

MOTS-c

View product

What GLP1-S is

What it's studied for

Laboratory handling — storage and reconstitution

How this batch is verified

Related research

For the full mechanistic profile, published references, and constraint notes on GLP1-S, see the GLP1-S research page. All references cited on that page are peer-reviewed primary literature.